Gastroenterology | Preclinical Developments

Morphic Therapeutic

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Morphic Therapeutic Presents Positive Preclinical Data Supporting Development of MORF-057 in Inflammatory Bowel Disease

Lead Product(s): MORF-057

Therapeutic Area: Gastroenterology Product Name: MORF-057

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 29, 2020

Details:

The data presented at DDW demonstrate that MORF-057 successfully targets the integrin α4β7 with high potency and selectivity.

Synlogic

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Synlogic Announces Termination of AbbVie Collaboration Agreement

Lead Product(s): Synthetic Biotic medicines

Therapeutic Area: Gastroenterology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Undisclosed

Partner/Sponsor/Collaborator: AbbVie Inc

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Termination May 21, 2020

Details:

Upon termination, Synlogic regains all rights to develop Synthetic Biotic medicines for the potential treatment of inflammatory bowel disease (IBD).

Morphic Therapeutic

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Morphic Presents Positive Preclinical Data Supporting MORF-057 as an Oral Inhibitor of the ?4?7 Integrin

Lead Product(s): MORF-057

Therapeutic Area: Gastroenterology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 14, 2020

Details:

Oral presentation at ECCO highlights MORF-057 as a potent, selective and orally available small molecule development candidate

Alpine Immune Sciences

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Alpine Immune Sciences Presents New Preclinical Data at 2020 Crohn’s & Colitis Congress ALPN-101 demonstrates efficacy in treatment of chr...

Lead Product(s): ALPN-101

Therapeutic Area: Gastroenterology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 24, 2020

Details:

The new data demonstrate the unique potency of ALPN-101 as measured by in vitro assays involving PBMC’s from patients with Crohn’s Disease or Ulcerative colitis and in vivo mouse models of colitis.

Daiichi Sankyo Co Ltd

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

JAPAN Japan

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Immunic Exercises Option to License Daiichi’s IMU-856

Lead Product(s): IMU-856

Therapeutic Area: Gastroenterology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Immunic Therapeutics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement January 08, 2020

Details:

The option and license agreement gives Immunic the exclusive rights to commercialization of IMU-856 in all countries.

Find

Find Novel Gastroenterology Drugs in Preclinical Development

Preclinical

Product Type

Companies

Morphic Therapeutic

Morphic Therapeutic Presents Positive Preclinical Data Supporting Development of MORF-057 in Inflammatory Bowel Disease

Synlogic

Synlogic Announces Termination of AbbVie Collaboration Agreement

Morphic Therapeutic

Morphic Presents Positive Preclinical Data Supporting MORF-057 as an Oral Inhibitor of the ?4?7 Integrin

Alpine Immune Sciences

Alpine Immune Sciences Presents New Preclinical Data at 2020 Crohn’s & Colitis Congress ALPN-101 demonstrates efficacy in treatment of chr...

Daiichi Sankyo Co Ltd

Immunic Exercises Option to License Daiichi’s IMU-856